Reports Q4 revenue $1.42M, two estimates $2.25M. Reports Q4 Gross margin for the fourth quarter of 2022 was $0.300M, compared to $(0.453M) in the fourth quarter of 2021."We made measurable progress at Hyperfine over the past year. We delivered $6.8 million in revenue in 2022, received multiple FDA clearances and international approvals, including CE Marking, in recent months, and saw a large number of publications and presentations on the clinical value of Swoop published and presented via major journals and meetings. We also implemented important measures to right size our business and extend our cash runway through the end of 2025, ending the year with a healthy balance sheet. These achievements lay the foundation for strong forward growth," said Maria Sainz, Chief Executive Officer and President of Hyperfine, Inc. "We believe the opportunity for Hyperfine to transform access to MRI scans across clinical uses and sites of service is incredibly compelling. Our team is dedicated to expanding commercial placements while focusing on additional innovation and clinical evidence. We look forward to growing our impact in the field of medical imaging and diagnostics."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HYPR:
- Hyperfine, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
- Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2022 Financial Results on March 21, 2023
- Hyperfine, Inc. Receives FDA Clearance for Updated Software to Further Improve Diffusion-Weighted Imaging
- Hyperfine receives FDA 510(k) clearance for Swoop system software update
- Hyperfine, Inc. Swoop® Portable MR Imaging® System Receives CE Marking After Meeting Comprehensive New EU MDR Regulations
